key: cord-0866912-dqynhcq7
authors: Kolahdouzan, Kasra; Chavoshi, Mohammadreza; Bayani, Reyhaneh; Darzikolaee, Nima Mousavi
title: Low dose whole lung irradiation for treatment of COVID-19 pneumonia: A systematic review and meta-analysis
date: 2022-05-07
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2022.04.043
sha: 420e1721fbb2e9a7cdbf12e1cc6be8fd0c1d41b8
doc_id: 866912
cord_uid: dqynhcq7

Background: Studies dating back to a century ago have reported using low-dose radiotherapy for the treatment of viral and bacterial pneumonia. In the modern era, since the COVID-19 pandemic began, several groups worldwide have researched the applicability of whole-lung irradiation (WLI) for the treatment of COVID-19. We aimed to bring together the results of these experimental studies. Methods and materials: We performed a systematic review and meta-analysis searching PubMed and Scopus databases for clinical trials incorporating WLI for the treatment of COVID-19 patients. Required data were extracted from each study. Using the random-effects model, overall pooled day-28 survival rate, survival hazard ratio, and intubation-free days within 15 days after WLI was calculated, and forest plots were produced. Results: Ten studies were identified, and eventually, five were included for meta-analysis. The overall survival hazard ratio was calculated to be 0.85 [0.46-1.57]. The pooled mean difference of intubation-free days within 15 days after WLI was 1.87, favoring the WLI group (CI: -0.02-3.76). Overall day 28 survival rate of patients receiving WLI for the eight studies with adequate follow-up data was 74% [95%CI:61-87]. Except for two studies, the other eight studies were assessed to have moderate to high risk of bias, and there were many differences between the design of studies, included patients, primary endpoints, outcome measurement methods, and reporting of the results. Conclusion: Despite a mild improvement in intubation-free days, WLI had no significant effect on patients' overall survival. Currently, we cannot recommend routine use of WLI for the treatment of moderate to severe COVID-19 patients.

COVID-19 disease caused by a large single-strand RNA virus from the beta coronavirus family was recognized in December 2019 and rapidly became a global issue (1) . Acute respiratory distress syndrome (ARDS), caused by a hyper-inflammatory state due to a cascade of cytokine release, is the leading cause of death in these patients (2) .

Anti-inflammatory effects of low-dose radiotherapy have been established in preclinical models. Low dose radiotherapy reduces proinflammatory mediators such as tumor necrosis factor (TNF)-α, selectins, and interleukin (IL)-beta 1, and at the same time increases the secretion of anti-inflammatory mediator transforming growth factor β1 (TGF-β1) and apoptosis mediator nuclear factor kappabeta (NF-κB) (3, 4) .

In a recent review by Calabrese et al. (5) , the authors report that low doses of radiation (<1 Gy) can induce nuclear factor erythroid 2-related transcription factor (Nrf2)-mediated cellular antioxidant states and also shift the balance of macrophages toward antiinflammatory M2 phenotype from the M1 pro-inflammatory subtypes. This change of balance has been shown to result in an increase of IL-10 and decrease of Interferon γ and IL-6 production, thus resulting in attenuation of the cytokine storm caused by the SARS-CoV-2 virus (6).

Low-dose radiotherapy was historically used for the treatment of viral and bacterial pneumonia (7) , dating back to about a century ago, and also benign inflammatory diseases like arthritis (8, 9) . This use of radiotherapy for non-malignant diseases was generally 6 before the development of the vast inventory of modern antibiotics and anti-inflammatory agents. After the COVID-19 pandemic challenged our modern resources, many clinicians looked for the long-forgotten and readily available low dose whole lung irradiation as a possible means of preventing excessive morbidity and mortality of COVID-19. Although successful vaccination programs and recently approved therapeutics have decreased the enthusiasm for investigating the efficacy of WLI in COVID-19, multiple trials have been conducted on this topic, and some are still underway. In order to sum up these new findings so far, we intended to run a systematic review and meta-analysis of studies incorporating WLI for the treatment of COVID-19 pneumonia.

This study was registered in the international prospective register of systematic reviews (PROSPERO, ID: XXX) and was designed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist (10) (Supplementary file #1).

A systematic search was done on the English-language medical literature using electronic bibliographic databases, the Scopus and PubMed, until the end of January 2022 to identify relevant original peer-reviewed full-length articles. The following terms were used in each database according to their search strategy: ("*radiation" OR radiotherapy) AND ("COVID*" OR "SARS-COV-2" OR coronavirus) AND ("pulmon*" OR lung) (Supplementary file #2). Further augmentation of the search was done by looking at the 7 included articles' references and forward citation searching for identifying updates of relevant studies. No time limit was considered for publications.

Following criteria were considered necessary for included articles:

1. Prospective phase 2/3 trials conducting whole lung radiotherapy in the treatment course of COVID-19 patients.

2. Following the patients for at least 28 days.

3. Provided adequate data to extract the Hazard ratio (HR), overall survival (OS) rate, and their standard error (SE).

Abstracts without full articles, unpublished studies, notes, letters, comments, and conference articles were excluded from the study.

Duplication removal was also done. Two researchers blindly reviewed the titles and abstracts to check the study's eligibility. Any study that had the agreement of both authors entered for full-text review. Both authors reviewed all full-texts, and if both agreed, the article was selected for meta-analysis. Discrepancies were solved by consensus or referred to a third senior researcher.

The investigating researchers independently extracted the following data: title, authors' name, journal title, year of publication, country of study, details of study design, included participant number, mean age, gender frequency, the severity of COVID-19, medical treatment received, duration of symptom onset, time of radiotherapy, dose, fraction, photon energy and radiotherapy technique, primary and secondary outcomes, ventilation free duration (VFD), time to clinical recovery, hospitalization duration, 8 follow up duration, level of C-reactive protein (CRP), O2 saturation, PaO2/FiO2, SpO2/FiO2, chest X-ray or CT severity, OS rate, and the number of event-positive/negative patients.

Two outcomes were selected for meta-analysis of studies with a control group; OS hazard ratio and intubation-free days in 15 days.

Data for these two outcomes were extracted from the relevant studies for each participant (from either the main text or supplemental data).

As detailed individual participant data (IPD) was unavailable, we needed to extract raw survival data from the survival curves presented within the articles for which the DigitizeIt software was used (11) , and the exact date of death or censored data and the change of OS rate were recorded. In one case, due to discrepancies between the statistical method used, reported results, and the illustrated OS curve, we emailed the corresponding author of the study to provide IPD. However, our request was not responded to, and the study was removed from the meta-analysis (12). Data extraction was completed by February 2022 for all outcomes of interest, whether included for meta-analysis or not.

Cochrane's "A revised Cochrane risk of bias tool for randomized trials" (RoB 2) and "Risk Of Bias In Non-randomized Studies -of Interventions" ROBINS-I tools were used for quality assessment of the randomized and non-randomized interventional studies, respectively (13, 14) . Also, the Methodological Index for Non-Randomized Studies (MINORS) risk of bias assessment tool (15) comprising of 8 domains was used for quality assessment of the single-arm non-comparative clinical trials, and a score of 0 to 2 was 9 appointed for each domain. A total score of 15 to 16 was considered high quality, 9 to 14 was considered moderate quality, and 0 to 8 was considered low quality.

The extracted raw OS and follow-up data, including event and censor dates from each included study, were used to reproduce individual life tables using IBM SPSS Statistics version 26. Kaplan-Meier curves were reconstructed and overlapped with the published curves to ensure accuracy of extracted IPD. Cox proportional hazards regression analysis was used to extract OS hazard ratios, standard errors, and confidence intervals from extracted IPDs. The Firth's penalized likelihood method was used for reduction of bias in Cox analysis when the number of events was zero in a subgroup. Also mean intubation-free days in 15 days and their standard errors were calculated for intervention and control groups. Using Review Manager (RevMan) version 5.3, a random-effects model was used to pool the OS HRs. Also, to calculate the pooled intubation-free days within 15 days after the intervention, the mean difference between intervention and control groups were pooled by the random-effects model. Heterogeneity assessment was performed by calculating Higgins' I 2 statistics and Cochran's Q test (with significance less than 0.1).

For calculation of aggregated day 28 OS rate in the intervention groups of all included studies, the "Metafor" package in R statistical analysis software (version 4.1.2, R Foundation for Statistical Computing, Vienna, Austria) was used (16) . 10 

A total of 641 studies were found after database search. Duplicate results were removed (149 studies). Four-hundred-ninety-two studies were reviewed by title and abstract, 16 were selected for full-text review, and ten were selected for the systematic review (qualitative analysis). A detailed process of screening is provided in Figure 1 . One study was suspected of having provided incorrect results due to discrepancy between methodological analysis, reported results, and illustrated OS figures and was therefore removed from the meta-analysis (12); however, the presented results are discussed separately.

Finally, nine studies (with a total of 151 WLI recipients) were considered eligible to enter the analysis of aggregated 28-day OS rate of patients receiving WLI (17-25) (quantitative analysis). Six studies had both intervention and control groups (115 participants in the intervention group and 98 participants as controls) (12, 17, 20-23). One of these controlled studies was the excluded study due to erroneously reported results. Eventually, four studies were included for meta-analysis of intubation-free days within 15 days after WLI and five studies for meta-analysis of OS hazard ratio. Study design characteristics and outcomes of interest in each study are shown explicitly in tables 1 and 2. 11 Detailed information on quality and risk of bias assessment for included studies is provided in Figure 2 

The pooled OS rate of the nine included studies was calculated 74% (confidence interval: 61-87%) in the WLI group ( Figure 3 ). The heterogeneity between the studies was significant (Q: 26.62, df = 8, =, p-value = 0.0008, I 2 : 76.11%, tau 2 : 0.028).

The pooled HR of the five included studies was 0.85 (CI: 0.46-1.57) ( Figure 4 ). There was no significant difference between the intervention and control groups considering the confidence interval. The confidence interval for Hess, 2021 study (20) was very wide due to a lack of terminal event in the control group which led to a large standard error. The heterogeneity of the studies was calculated as mild in this issue (Q: 1.61, df=4, p-value=0.81, I 2 : 0%). However, it should be mentioned that the low heterogeneity result could be due to the small number of studies.

The pooled mean difference of intubation-free days during 15 days after WLI between intervention and control groups was 1.87 days favoring the WLI group (CI: -0.02-3.76) ( Figure 4 ). The results show that intubation-free days was relatively higher in the WLI 12 group. The heterogeneity of the studies was also minimal (Q:1.33, df=3, p-value:0.72, I 2 : 0%, tau 2 :0). Again, we should mention that the minimal heterogeneity could be related to the small number of studies.

Ortiz et al. (12) treated 30 moderate to severe patients with 1 Gy WLI and compared the outcomes with a matched control group of 29 patients. They reported a crude OS rate of 72.5% in the intervention group versus 41.4% in the control group (p value:0.05). In an unplanned subgroup analysis based on the severity of ARDS, the crude OS rate in moderate and severe patients was 100% and 22% in the intervention group versus 40% and 0% in the control group, respectively (p-value: 0.01 and 0.9).

The final 28-day OS rates varied significantly between studies, from 32% in Mousavi et al. (22) to 90% in Sharma et al. (25) and Hess et al. (21) .

Ortiz et al. reported a 33% need for mechanical ventilation in the intervention group versus 58% in the control group (p value:0.51); however, in a subset analysis of moderate severity patients, none of the patients in the intervention group needed mechanical ventilation compared to 45% of the controls (p value<0.001). This difference was not statistically significant in the severe ARDS subgroup of their patients (100% vs. 89%, p value:0.47). Ganesan et al. (17) reported that 5(15%) and 4(23%) of their patients in the 13 intervention and control groups respectively, required mechanical ventilation and later succumbed to the disease. Mousavi et al. (22) reported that six patients (54.5%) of the WLI group required intubation after WLI compared with 4 (36.4%) of the control group after allocation. In Papachristofilou's (23) study, 0 of the three non-intubated patients needed intubation after WLI compared with 3 of the six non-intubated patients in the sham WLI group. The first cohort of Hess et al. 

Three studies with a control group reported time to clinical recovery (TTCR) defined as time to wean from supplemental oxygen and remain so for at least 12 hours. Hess (23) reported that 36% of patients in each group were weaned off ventilation, and 14% in each group were discharged from the hospital during the study period. Also, Mousavi et al. (22) reported that 27.3% of patients in each group 14 were eventually discharged from the hospital. The median time from WLI to discharge was very different across the studies, reported to be between 6 to 15 days. Ganesan et al. (17) reported that time from intervention to discharge was 7 [5.6-8.3] days and 13 [12] [13] [14] days in the WLI and control arms, respectively (log-rank p value <0.001), whereas it was 12 days [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] in the WLI and 20 days in the control group (p value:0.19) for Hess et al. trial (21) .

Six studies reported data on oxygenation status (i.e., O2 saturation, PaO2/FiO2 (P/F ratio), and SaO2/FiO2 (S/F ratio)) of patients after receiving WLI. Papachristofilou et al. (23) reported no significant difference in 24-hour change of P/F ratio between the WLI and control groups (median of +5 in WLI group vs. +9 in the control group, p-value: 0.49), whereas Arenas et al. (19) reported a significant improvement in one week (p value<0.001). They also reported a significant increase in SpO2 in one day, one week, and one month after WLI (p value≤0.017). Mousavi et al. (22) reported an insignificant 2.5% rise of SpO2 24 hours after WLI. Ameri et al. (18) also reported a median 2.5% improvement of SpO2 in 90% of their patients within 24 hours. Sanmamed et al. (24) reported a significant improvement of S/F ratio 3 and 7 days after WLI (P-value: 0.01). Also, Ganesan et al. (17) reported a significant improvement of the S/F ratio from baseline in 3, 7, and 14 days after WLI which was significantly higher than the control group on days 7 and 14 (p value ≤ 0.001). 15 Numerous studies have reported a significant correlation between radiologic findings and COVID-19 patients' clinical condition and prognosis; therefore, a radiographic improvement could be a reliable indicator of clinical recovery (26) (27) (28) (29) .

Of the ten identified studies, six reported whether or not a radiological difference was observed. Although their assessment methods and imaging modalities differed significantly and some presented subjective results rather than objectively measured findings, we will report the most important findings of these studies.

Mousavi et al. (22) reported a chest X-ray score change in the WLI group of -2.2±3.1 versus 0.7±3.9 in the control group (p-value: 0.085), which indicated a trend for improvement of chest X-rays in patients receiving WLI. They reported that the final chest X-ray score in the WLI group was significantly lower (fewer infiltrations) than that of the control group (8.7±2.5 versus 12.3±3.3, p-value: 0.016). Sanmamed et al. (24) reported that the objectively assigned CT scores significantly improved between the first and the third CT scans on day seven after WLI (P-value: 0.03). Also, Ganesan et al. (17) reported that the pre-WLI CT score of 16 [IQR: [15] [16] [17] improved to 12[IQR:10-14] on day 14 after WLI (p value <0.001). This improvement of CT score from baseline to day 14 was significantly higher for the intervention group (p value:0.011). Arenas et al. (19) reported that in their single-arm cohort of 36 patients, the CT scan of surviving patients one week after WLI showed significant improvement; however, they did not present any subjective or objective data. 16 Despite these positive studies, Hess et al. reported that through a subjective assessment of chest X-rays and ARDS scale scores, radiographic improvement was not observed in any of their cohorts (p-value: 0.17, 0.72 for cohorts 1 (21) and 2 (20), respectively).

We did not enter these data into our meta-analysis because of the heterogeneity of imaging modalities and different methods of radiographic assessment incorporated by the studies.

Of the ten included studies, 7 reported CRP changes after implementation of WLI. Unfortunately, each study had its unique timepoints for evaluating CRP change, and we could not perform a meta-analysis on this relatively important inflammatory biomarker. (21), reported that CRP levels decreased 11% more rapidly in the intervention group relative to the control group 7 days after WLI (p value:0.01). In their second cohort (20), this decline was again superior in the intervention group (p-value: 0.02).

Mousavi et al. observed a 14% decrease [range: -67% to 43%] in CRP within 4 days in WLI group compared with an 8% increase [range: -52% to 30%] in their controls. Three non-comparative studies also reported CRP changes after intervention in their participants. Sanmamed et al. (24) reported that CRP decreased seven days post-intervention; however, non-significant. Arenas et 17 al. (19) reported that CRP decreased significantly in all 36 patients receiving WLI within 24 hours (p value<0.05). Ameri et al. (18) reported that 30% of their participants had decreased CRP one to two days after WLI.

Acute adverse events were reported in 3 studies. Hess et al. (21) reported one (10%) grade 1 nausea. Papachristofilou et al. (23) reported a 66% reduction in median lymphocyte count in the WLI group compared with a 10% reduction in the control group (p value<0.01). Also, Sanmamed et al. (24) reported two grade 2 and one grade 4 lymphopenia in their cohort of 9 patients after WLI.

The highest lifetime risk of WLI-induced risk of lung cancer and major coronary events is estimated to be 6% and 3%, respectively, in younger patients (50 to 60 years old) with risk factors (30) .

Risk of bias assessment was done using Cochrane's RoB 2 tool for evaluation of the two randomized trials included (Figure 2 ). Papachristofilou et al. (23) used a sham-RT group as controls and blinded patients and caregivers. This study was assessed to have a low risk of bias in all domains; however, some concerns remained in the domain related to the randomization process due to the observed differences in baseline characteristics between the intervention and control groups. The frequency of pulmonary diseases (36% vs. 9%) and male sex (91% vs. 64%) was higher in the intervention group, and the frequency of treatment with remdesivir (36% 18 vs. 64%) was higher in the control group (significance level not presented). All of these factors favored the control group. Ganesan et al. (17) also conducted a non-blinded randomized 2:1 parallel group clinical trial after a successful phase 1 exploratory phase. This study was also assessed to have a low risk of bias despite some concerns remaining for the randomization process due to the observed differences between the intervention and control groups regarding participants' age and comorbidities.

Cochrane's ROBINS-I tool was used to evaluate the non-randomized comparative studies (4 studies) ( Figure 2 ). Studies evaluated with this tool were assessed to have an overall serious (3 studies) and critical (1 study) risk of bias for OS outcome and overall serious (2 studies) and moderate (1 study) risk of bias for intubation-free days outcome. Both cohorts reported by Hess et al. (20, 21) were assessed to have a serious risk of bias because they permitted controls to be selected from other concurrent trials of COVIDdirected therapies, and a significant difference was observed between the intervention and control groups on this regard (p-value: 0.02). Also, the domain of outcome assessment for OS was assessed to have a moderate risk of bias in their cohorts because the starting time-point for evaluation of the OS for the control groups was measured from the first day of anti-COVID therapy (or the first day of hospitalization in patients not receiving any specific treatment) compared to the first day of WLI in the intervention group. Although the authors tried to justify this issue with a secondary analysis incorporating a similar starting time point (i.e., day of hospital admission) and showed no significant lead-time bias, there remains an undeniable inherent bias due to the design of this study. 19 Mousavi et al.'s (22) study was also assessed to have a serious overall risk of bias for OS outcome. This study was assessed to have a serious risk of reporting bias because of deviations from their initially planned outcomes according to the registered protocol 

There was a minor asymmetry in the funnel plot of publication bias (Supplementary Figure 1) . The regression test also showed an almost significant publication bias among the studies (P-value=0.054). Although there seems to be a significant publication bias in 20 the first look, there are some critical considerations. First, the power of the test is low when the number of studies is less than 10 (31). Second, the high level of heterogeneity could interfere with the test results (32) . More attention to the plot shows that the asymmetry is on the areas of higher significance (light and dark gray zones), which means that asymmetry is probably due to factors other than reporting bias (31, 33) . However, we believe that reporting bias could also exist even considering the mentioned issues.

All studies have been performed rapidly during 2020-2021. Sampling error is also another essential issue considering small-size studies. On the other hand, there is no study from eastern Asia, Africa, or Oceania.

Our meta-analysis did not demonstrate any OS benefit for WLI compared to usual anti-COVID-19 medications (HR: 0.85, [95%CI: 0.46-1.57]). However, an almost significant reduction of about two days in post-radiation requirement of endotracheal intubation was observed within 15 days after implementation of the WLI.

The included studies generally looked for answers to different questions, and the primary outcomes differed across the studies ( Table 1 ). The primary outcomes consisted of clinical recovery (duration of hospital stay, need for ICU admission or mechanical ventilation, etc.), clinical improvement of oxygenation status (SpO2, P/F or S/F ratio), radiological improvement, and mortality rate. 21 Only six studies had a control group, enabling a comparative analysis of intended outcomes. Two of these studies were randomized (17, 23) and one was double-blinded, incorporating a sham-RT group as controls (23), but the other 4 used a non-randomized matched control group (12, 20-22). Due to the heterogeneity of studies and their reported outcomes of interest, we could only use OS hazard ratios and the number of intubation-free days within 15 days after intervention for the meta-analysis. Also, a noncomparative rate of day-28 OS was meta-analyzed for all included studies (9 studies). When pooled together, the 28-day OS rate translated into 74% [95%CI:61-87] ranging from 32% to 90%. This difference in OS rate might be due to heterogeneity of the studies regarding patients' severity of ARDS, baseline comorbidities, different medications received by patients, and different timelines and settings for the treatment of patients.

Hess et al. were the only researchers that employed a radiation dose higher than 1 Gy. It has been previously noted that doses >1 Gy might shift the population of macrophages into the pro-inflammatory M1 phenotype (34) that might be the underlying reason for no significant resolution of radiographic infiltrations. Also, in a preclinical bleomycin-induced pneumonitis model, 1.5 Gy of WLI was shown to be incapable of reducing mice lung capacity deterioration as measured by CT scanning compared with 1 Gy dose (35).

Moreover, mice with moderate lung injury recovered significantly more than the severe pneumonitis cases. Also, in their second cohort, Hess et al. (20) selected more favorable controls and excluded controls who experienced rapid clinical decline at admission, thus introducing an undeniable selection bias which was probably the reason behind the lower mortality rate in this group. 22 Papachristofilou et al. (23) were the only group incorporating sham WLI as the control group for their double-blind, randomized trial.

Although the treatment methodology was superior to the other studies, they treated patients with one anteroposterior field, which raises doubts about appropriate dose distribution to the affected lung volume. Also, patients in the intervention group comprised of more males, had more frequent baseline pulmonary disease, and were treated with remdesivir less frequently. These differences, despite the randomized nature of the study, could have biased the observed results.

Mousavi et al. (22) and Sanmamed et al. (24) treated their patients with WLI at a median of 10 and 52 days after hospital admission, which is exceptionally more prolonged than the other studies, and the patients treated in these two cohorts might have been at later stages of ARDS especially in the former study as stated by the authors and evident through their mortality rates.

We should keep in mind that OS was the primary endpoint in none of the analyzed studies. Also, two of the five meta-analyzed studies (for OS) included severe cases of ICU admitted patients under mechanical ventilation (22, 23) in which the observed fatal outcomes could be dictated by multiple major complications of SARS-CoV-2 that are irreversible by WLI after some point during the disease course. Uniform reporting of critical baseline characteristics such as objective scoring systems for disease severity and present comorbidities across all studies, would have presented valuable prognostic information.

We searched the Clinicaltrials.gov for any relevant studies of WLI in COVID-19 patients. Thus far, ten trials (5 of them with a matched control group), one case series (36), and a case report (37) have been published, but when searching the registered trials, we found 23 nine more groups from the USA, Europe, and India that are still recruiting COVID-19 patients for WLI (Supplementary Table 2 ). The largest of these studies aim to recruit 100 and 150 participants (NCT04466683 and NCT04433949, respectively) and their results might provide more evidence on efficacy of WLI in COVID-19 patients. As previously stated, despite some benefits noted in different trials for WLI in oxygenation, radiologic, and clinical status, our meta-analysis does not establish a significant role of WLI on OS or length of intubation-free days; two seemingly critical clinical endpoints. In contrast to the era when every effort was considered welcome in the hope of finding a solution to diminish the high burden of the pandemic sufferings, major ethical issues remain regarding continuing patient enrollment in the ongoing complicated and laborious WLI trials. Given the currently available novel therapeutics, antivirals, and extensive vaccination programs with proven efficacy in COVID-19 prevention and treatment, the community should reassess the marginal gain versus risk of additional prospective studies of whole lung irradiation.

The main limitation of this systematic review and meta-analysis was the heterogeneity of available studies researching the clinical applicability of WLI in COVID-19 pneumonia. The studies had different designs and generally included patients with different severity of disease, and each study included different endpoints and different methods for measuring them. The fact that hazard ratios and associated confidence intervals were not reported was another limitation that compelled us to extract these data indirectly from the studies. Another important limitation of this study, was the unavailability of individual participant data for each trial that, if 24 accessible, could have reduced ambiguities that were confronted when assessing the studies, and probably more other outcomes of interest could be explored. Except for one study with a randomized, double-blinded design with a sham-WLI group and another nonblinded randomized study that were assessed to have a low risk of bias, others were either non-randomized comparative trials with matched controls or single-arm experimental trials that were assessed to have moderate to high risk of bias. Another important unmeasurable confounder is the different time ranges and geographic regions in which the studies were conducted (Table 1 ). These differences should be taken into account as available anti-COVID medications, workforce pressures on healthcare systems, general ICU management quality, and pace of vaccination programs all differed extensively during periods of time and across countries.

Our study shows that in spite of some clinical benefit reported in different trials, WLI could not change the survival probability of moderate to severe COVID-19 patients. Whether there is a specific subgroup of COVID-19 patients in which WLI would be more efficacious could not be answered yet. Nevertheless, we can speculate that very severe cases of COVID-19 may not benefit from WLI, and for mild cases, there is no justifiable rationale to pose patients to the risk of radiation-induced latent malignancy while the disease can be managed with available medical treatment. 

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

COVID-19: consider cytokine storm syndromes and immunosuppression

Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved

Functional and molecular aspects of anti-inflammatory effects of low-dose radiotherapy

Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations

Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia

How radiotherapy was historically used to treat pneumonia: could it be useful today?

Radiotherapy treatment of human inflammatory diseases and conditions: Optimal dose

Analgesic radiotherapy for osteoarthrosis of digital joints and rhizarthrosis

Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P)

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

The clinical efficacy of low-dose whole-lung irradiation in moderate-to-severe COVID-19 pneumonia: RTMX-20 trial

RoB 2: a revised tool for assessing risk of bias in randomised trials

ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions

Methodological index for non-randomized studies (minors): development and validation of a new instrument

Package 'metafor'. The Comprehensive R Archive Network Package

Whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)

Low-Dose Whole-Lung Irradiation for COVID-19 Pneumonia: Final Results of a Pilot Study

Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR non-randomized prospective trial (IPACOVID trial)

Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir

Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia

Low-dose whole-lung irradiation in severe COVID-19 pneumonia: a controlled clinical trial

Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia: A Randomized Double-Blind Study

Low-Dose Radiation Therapy in the Management of Coronavirus Disease 2019 (COVID-19) Pneumonia (LOWRAD-Cov19): Preliminary Report

Low-dose radiation therapy for COVID-19 pneumonia: A pilot study

Correlation of chest radiography findings with the severity and progression of COVID-19 pneumonia

Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China

Prognostic Factors of Initial Chest CT Findings for ICU Admission and Mortality in Patients with COVID-19 Pneumonia

Clinico-Radiological Evaluation and Correlation of CT Chest Images with Progress of Disease in COVID-19 Patients

Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy

Patients With Different Background Risks

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemoand immunotherapies

CXR: chest X-ray, ICU; Intensive Care Unit, ICU ad; ICU admitted, IL-6: interleukin-6, MV: mechanical ventilation/megavolt